There have been clinical trials of LSD-1 inhibitors for other cancers, particularly for small-cell lung cancer (SCLC) and acute myeloid leukaemia (AML), demonstrating various potential uses and anti-tumour effects [118,119]. Here, KDM1A is linked to small cell lung carcinoma.